Ovid Therapeutics Inc (OVID) Reports Q3 2023 Financial Results

Company extends cash runway into 2026 and anticipates five clinical and regulatory milestones in the next 15 months

Related Keywords

United States , ,Ovid Therapeutics Inc ,Clinical Research Pipeline Updates ,David ,Milestone Payments ,Stockholders ,Net Loss ,Ovid Therapeutics ,